



# Pfizer Announces 2019 Global Breast Cancer Competitive Research Grant Program

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.



## Competitive Grant Program Eligibility

<b>Geographic Scope</b>	<ul style="list-style-type: none"> <li>Global, institutions in all countries and geographic regions are eligible to apply</li> </ul>
<b>Applicant Eligibility Criteria</b>	<p>To be eligible:</p> <ul style="list-style-type: none"> <li>The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent)</li> <li>Applicant must be affiliated with a host institution</li> <li>Both early career and experienced investigators are encouraged to apply, and consideration will be given to all proposals meeting the selection criteria</li> </ul>

## Requirements

<b>Clinical Area</b>	Oncology - Advanced Breast Cancer
<b>Area of Interest / Research Focus</b>	<p>The intent of this Request for Proposal (RFP) is to invite investigators from across the globe to submit innovative proposals focusing in the following areas:</p> <ul style="list-style-type: none"> <li>In hormone receptor positive metastatic breast cancer:             <ul style="list-style-type: none"> <li>Treatment strategies to overcome palbociclib + endocrine treatment resistance</li> <li>Novel treatment concepts of adding immuno-oncology (IO) agents to palbociclib + endocrine therapy</li> </ul> </li> <li>In metastatic breast cancer:             <ul style="list-style-type: none"> <li>Novel treatment strategies utilizing talazoparib beyond gBRCA mutation</li> <li>Novel treatment strategies to overcome talazoparib resistance or improve tumor sensitization to talazoparib</li> </ul> </li> </ul> <p>In addition, incorporation of the following into the proposed clinical study would be of interest: a correlative/biomarker component using paired biopsy samples (e.g pre- and post- treatment), cfDNA assessment, predictive signatures beyond gBRCAmut in advanced breast cancer (such as tumor BRCA/PALB2mut or HRD), or PK/PD biomarkers to explore potential mechanisms of resistance/response or synergistic effect.</p>

<p><b>Expected Approximate Monetary Range of Grant Applications</b></p>	<ul style="list-style-type: none"> <li>• A total of \$5 million USD is allocated to this research grants program</li> <li>• Applications will be reviewed by an independent review panel. 6-8 clinical studies will be selected for funding.</li> <li>• The amount of the grant Pfizer will be prepared to fund for any project will depend upon the external review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the approval notification</li> </ul>
<p><b>Key Dates</b></p>	<ul style="list-style-type: none"> <li>• RFP release date: May 30, 2019</li> <li>• Letter of Intent (LOI) due date: October 15th, 2019 Please note the deadline is midnight Eastern Time (New York, GMT -5).</li> <li>• Anticipated LOI Notification Date: November 20, 2019</li> <li>• Full Proposal Deadline: January 9, 2020 *Only accepted LOIs will be invited to submit full proposals Please note the deadline is midnight Eastern Time (New York, GMT -5).</li> <li>• Anticipated Full Proposal Notification Date: February 28, 2020</li> </ul> <p><b>NOTE:</b> Grant funding will be distributed following execution of fully signed Letter of Agreement.</p>
<p><b>How to Apply</b></p>	<ul style="list-style-type: none"> <li>• Please go to <a href="http://www.cybergrants.com/pfizer/loi">www.cybergrants.com/pfizer/loi</a> and sign in. First-time users should click “REGISTER NOW”.</li> </ul> <p>Requirements for submission:</p> <ul style="list-style-type: none"> <li>• Select the following Competitive Grant Program Name: 2019 Global Breast Cancer Competitive Research Grant Program</li> <li>• Complete all required sections of the online application. See Appendix A for additional details</li> <li>• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page</li> </ul>
<p><b>Questions:</b></p>	<ul style="list-style-type: none"> <li>• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline Waldrop (Jacqueline.waldrop@pfizer.com), with the subject line “2019 Global Breast Cancer Competitive Research Grant Program”</li> <li>• Please click <a href="#">here</a> to view Frequently Asked Questions regarding the Competitive Grant Program</li> </ul>
<p><b>Mechanism by which Applicants will be Notified:</b></p>	<ul style="list-style-type: none"> <li>• All applicants will be notified via email by the dates noted above</li> <li>• Applicants may be asked for additional clarification during the review period</li> </ul>

## Appendix A

### Letter of Intent Requirements

The Letter of Intent (LOI) will be accepted via the online application. When answering the LOI questions in the application please keep the following in mind:

<b>Goals and Objectives</b>	Provide the main goal of the study and the study population. Provide a detailed definition that is directly linked to the primary objective
<b>Assessment of Need for the Project</b>	This should reflect your study rationale. Provide a brief description of the medical question and the rationale of how this trial addresses the question
<b>Target Audience</b>	Describe the primary audience(s) targeted for this project. For Investigator Sponsored Trials, please specify the age, gender and other demographic information for trial population  Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population
<b>Project Design and Methods</b>	Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study; include inclusion/exclusion criteria, treatment plan and statistical plan
<b>Innovation</b>	Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project
<b>Evaluation and Outcomes</b>	Specify type and frequency of safety, efficacy, and outcome measures. Also indicate the method(s) used to assess measures
<b>Anticipated Project Timeline</b>	Provide an anticipated timeline for your project including project start/end dates
<b>Additional Information</b>	If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here
<b>Organization Detail</b>	This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.